NO20061419L - Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser - Google Patents

Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser

Info

Publication number
NO20061419L
NO20061419L NO20061419A NO20061419A NO20061419L NO 20061419 L NO20061419 L NO 20061419L NO 20061419 A NO20061419 A NO 20061419A NO 20061419 A NO20061419 A NO 20061419A NO 20061419 L NO20061419 L NO 20061419L
Authority
NO
Norway
Prior art keywords
lower alkyl
hydrogen
trifluoromethyl
halogen
group
Prior art date
Application number
NO20061419A
Other languages
English (en)
Inventor
Henri Stalder
Emmanuel Pinard
Simona Maria Ceccarelli
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20061419L publication Critical patent/NO20061419L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår forbindelser med den generelle formel (I) hvor A-A er -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O- eller -O-CH2-; X er hydrogen eller hydroksy; R1 er aryl eller heteroaryl, usubstituert eller substituert med én eller flere substituenter valgt fra gruppen som består av lavere alkyl, lavere alkoksy, halogen eller trifluormetyl; R2 er aryl eller heteroaryl, usubstituert eller substituert med én eller flere substituenter valgt fra gruppen som består av lavere alkyl, lavere alkoksy, halogen eller trifluormetyl, eller er lavere alkyl, -(CH2)n-cykloalkyl, -(CH2)n-CF3, -(CH2)p-O-lavere alkyl, -(CH2)i,2-fenyl, eventuelt substituert med halogen, lavere alkyl, lavere alkoksy eller trifluormetyl, eller er -(CH2)P-NR'R", hvor R' og R" sammen med N-atomet danner en heterocyklisk ring, valgt fra gruppen som består av piperidin, morfolin, tiomorfolin eller 1,1-diokso-tiomorfolin; R3, R4 er uavhengig av hverandre hydrogen, lavere alkyl, fenyl eller benzyl; R5 er hydrogen, lavere alkyl eller benzyl; R6 er hydrogen eller lavere alkyl; n er 0, 1 eller 2; og p er 2 eller 3; og farmasøytisk akseptable syreaddisjonssalter derav for behandling av psykoser, smerte, nevrodegenerativ dysfunksjon relatert til hukommelse og læring, schizofreni, demens og andre sykdommer hvor kognitive prosesser er svekket, så som oppmerksomhetssvikt-lidelser eller Alzheimers sykdom.
NO20061419A 2003-10-23 2006-03-28 Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser NO20061419L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03024415 2003-10-23
PCT/EP2004/011552 WO2005040166A1 (en) 2003-10-23 2004-10-14 Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
NO20061419L true NO20061419L (no) 2006-07-14

Family

ID=34486099

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061419A NO20061419L (no) 2003-10-23 2006-03-28 Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser

Country Status (19)

Country Link
US (1) US7189850B2 (no)
EP (1) EP1678177B1 (no)
JP (1) JP4490434B2 (no)
KR (1) KR100798161B1 (no)
CN (1) CN100467468C (no)
AR (1) AR046186A1 (no)
AU (1) AU2004283843B2 (no)
BR (1) BRPI0415833A (no)
CA (1) CA2543308C (no)
CO (1) CO5690643A2 (no)
DE (1) DE602004010419T2 (no)
ES (1) ES2297502T3 (no)
IL (1) IL174734A (no)
MX (1) MXPA06004305A (no)
NO (1) NO20061419L (no)
RU (1) RU2006117368A (no)
TW (1) TW200526662A (no)
WO (1) WO2005040166A1 (no)
ZA (1) ZA200603221B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2602626A1 (en) * 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
DE102005038141A1 (de) * 2005-08-12 2007-02-15 Grünenthal GmbH Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate
CN101395142B (zh) 2006-03-08 2012-03-28 弗·哈夫曼-拉罗切有限公司 4-氨基-1,5-取代的1,5-二氢-咪唑-2-酮
US20090326027A1 (en) * 2006-03-16 2009-12-31 Steven Coulton N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors
GB0607398D0 (en) * 2006-04-12 2006-05-24 Glaxo Group Ltd Compounds
CA2654262A1 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
WO2008092878A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
WO2008092874A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
JP2010517962A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
GB0701985D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
TW200846328A (en) * 2007-02-01 2008-12-01 Glaxo Group Ltd GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
EP2108018A2 (en) * 2007-02-01 2009-10-14 Glaxo Group Limited 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
AU2008270444A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
US9413889B2 (en) * 2007-09-18 2016-08-09 Telecommunication Systems, Inc. House number normalization for master street address guide (MSAG) address matching
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
UA104611C2 (en) * 2009-01-27 2014-02-25 Ф. Хоффманн-Ля Рош Аг Aroylamino- and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR102051881B1 (ko) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2844275A1 (en) 2011-08-05 2013-02-14 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
JP2015157764A (ja) * 2012-06-14 2015-09-03 大正製薬株式会社 グリシントランスポーター阻害物質
HK1222766A1 (zh) 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2015103060A1 (en) 2014-01-06 2015-07-09 Algomedix, Inc. Trpa1 modulators
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
MA39888A (fr) * 2014-04-24 2017-03-01 Dart Neuroscience Cayman Ltd Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
TWI601712B (zh) 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
RS67557B1 (sr) 2018-08-24 2026-01-30 Pharmacosmos Holding As Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170446T3 (es) * 1997-12-05 2002-08-01 Hoffmann La Roche Derivados de 1,3,8-triaza-espiro(4,5)decan-4-ona.
EP0921125B1 (en) * 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
CA2515838A1 (en) * 2003-02-17 2004-08-26 F. Hoffmann-La Roche Ag Piperidine-benzenesulfonamide derivatives

Also Published As

Publication number Publication date
JP4490434B2 (ja) 2010-06-23
JP2007509097A (ja) 2007-04-12
DE602004010419D1 (de) 2008-01-10
CA2543308C (en) 2012-03-06
RU2006117368A (ru) 2007-12-10
CO5690643A2 (es) 2006-10-31
MXPA06004305A (es) 2006-06-05
AU2004283843B2 (en) 2010-04-22
TW200526662A (en) 2005-08-16
KR20060076317A (ko) 2006-07-04
BRPI0415833A (pt) 2007-01-02
WO2005040166A1 (en) 2005-05-06
ES2297502T3 (es) 2008-05-01
CN100467468C (zh) 2009-03-11
DE602004010419T2 (de) 2008-10-09
US7189850B2 (en) 2007-03-13
KR100798161B1 (ko) 2008-01-28
IL174734A0 (en) 2006-08-20
AU2004283843A1 (en) 2005-05-06
EP1678177A1 (en) 2006-07-12
US20050107373A1 (en) 2005-05-19
CA2543308A1 (en) 2005-05-06
CN1871238A (zh) 2006-11-29
EP1678177B1 (en) 2007-11-28
ZA200603221B (en) 2009-04-29
IL174734A (en) 2010-05-31
AR046186A1 (es) 2005-11-30

Similar Documents

Publication Publication Date Title
NO20061419L (no) Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser
NO20060975L (no) 1-Benzoyl-piperazinderivater som glycin gjenopptaksinhibitorer for behandling av psykoser
TW200505907A (en) Piperidine-benzenesulfonamide derivatives
NO20073667L (no) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser
AU611997B2 (en) 3,4 amino quinolines and 4 amino 3 nitroquinolines
DK2297120T3 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of Alzheimer's disease
SE0202134D0 (sv) Therapeutic agents
NO20072833L (no) Bi- og tricykliske substituterte fenylmetanoner som glycinetransportor I-(Glyt-1)-inhibitorer for behandling av Alzheimers sykdom
NO20015686D0 (no) Nye forbindelser, deres anvendelse og fremstilling
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
JP2002504484A (ja) 新規化合物
NO20081056L (no) Nye, heterosykliske NF-kB-inhibitorer
DE69835877D1 (de) Trizyklische verbindungen
JP2011510972A5 (no)
CA2488761A1 (en) 2-benzofuryl or benzothiophenyl-quinuclidinyl amides as nicotinic acetylcholine receptor inhibitors
RU2008148165A (ru) Замещенные производные фенилметанона
AU2004215523B2 (en) Method for Preparing Acid Addition Salts of Polyacidic Basic Compounds
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
NZ243340A (en) 2-aminopyrimidine-4-carboxamide derivatives, pharmaceutical compositions
Alagarsamy et al. Synthesis of 4-butyl-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
EA201000666A1 (ru) Производные 5-замещенных индол-3-карбоновой кислоты, обладающие противовирусной активностью, способ их получения и применение
Alagarsamy et al. Synthesis and pharmacological investigation of novel 4‐(4‐Ethyl phenyl)‐1‐substituted‐4H‐[1, 2, 4] triazolo [4, 3‐a]‐quinazolin‐5‐ones as new class of H1‐antihistaminic agents
RU2007125380A (ru) Сульфанил-замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения неврологических и психоневрологических заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application